retatrutide nonalcoholic steatohepatitis trial Liraglutide safety and efficacy in patients with non-alcoholic (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study NASH Pipeline

Psychiatry Res Neuroimaging

Microdosing is often being explored by women who are somewhat metabolically flexible, not seeking major weight loss, and interested in using these drugs more like a supplement but thats where things get complicated

What you are getting with this stack is a fat-loss foundation paired with a tissue-quality foundation

Case data shows that patients who combine GLP-1 medications with resistance training and adequate protein can lose over 90 percent of their weight from fat, keeping muscle loss under 9 percent, which is similar to calorie restriction alone

While GLP-1 therapies alone have a low risk of causing low blood sugar, adding insulin or sulfonylureas to the mix calls for careful dosage adjustments and close monitoring

Semaglutide has also demonstrated impressive results, with 59% NASH resolution in a phase 2 trial and substantial reductions in hepatic fat content measured by MRI